Delivery Order SPE2DB22D2206-SPE2DB24FHW37

Award Date 6/21/24
Potential Completion Date 7/15/24
Potential Value $51K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, for the supply of ULTOMIRIS 1,100 MG/11 ML VIAL 11ML medical products. The contract, valued at $192,762.90, was awarded by the Defense Logistics Agency (DLA) Troop Support Medical, a component of the U.S. Department of Defense. The contract is a delivery order type with a firm fixed price pricing structure, and has an ultimate completion date of March 25, 2025....
This federal contract award to AmerisourceBergen Drug Corp's Corporate Office Division is for the delivery of ULTOMIRIS 1,100 MG/11 ML VIAL 11ML, a pharmaceutical product. The contract has a ceiling value of $93,652.38 and an ultimate completion date of July 30, 2024. It was awarded by the Defense Logistics Agency (DLA), a defense agency, on July 9, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $46,826.19, is for the delivery of ULTOMIRIS 1,100 MG/11 ML VIAL 11ML, a specialty pharmaceutical product. This is a delivery order contract with a firm fixed price pricing type, with a period of performance running through November 20, 2024. The contract is not designated as a set-aside and...
This is a $17,523.90 firm fixed price delivery order contract awarded to AmerisourceBergen Drug Corp by the Defense Logistics Agency (DLA) for the procurement of ULTOMIRIS 1,100 MG/11 ML VIAL 11ML. The contract has an ultimate completion date of April 14, 2025. This award is associated with a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical valued at $999,999,999, which serves as a primary vehicle for providing a comprehensive range of...
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $97,908.23 firm fixed-price delivery order is for the supply of 1,100 mg/11 ml vials of the drug ULTOMIRIS. The contract has a ceiling value of $97,908.23 and a period of performance through December 6, 2024. This contract award is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with...
This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $46,826.19, is for the supply of ULTOMIRIS 1,100 MG/11 ML VIAL 11ML, a specialty medication, with a completion date of September 10, 2024. The contract is a Delivery Order under a broader Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA Troop Support Medical, valued at up to $999,999,999 through December...
This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA) Troop Support Medical. The contract, valued at $4,779.26, is for the delivery of ULTOMIRIS 300 MG/3 ML VIAL 3ML. It is a Firm Fixed Price Delivery Order contract with an ultimate completion date of April 21, 2025. This award is not associated with a set-aside program. Amerisourcebergen Drug Corp is a for-profit organization...
This federal contract award, valued at $44,249.70, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of ULTOMIRIS 300 MG/3 ML VIAL 3ML, a specialty medication, with a completion date of February 21, 2025. The contract does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of ULTOMIRIS 1,100 MG/11 ML VIAL 11ML, a pharmaceutical product. The contract has a ceiling value of $52,571.70 and a period of performance extending until May 29, 2025. It is a firm fixed-price delivery order contract with no set-aside designation, indicating open competition....
This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, Corporate Office Division. The contract is for the delivery of ULTOMIRIS 1,100 MG/11 ML VIAL 11ML, a specialty pharmaceutical product, with a ceiling value of $46,826.19. The contract has a firm fixed price pricing type and an ultimate completion date of October 16, 2024. This award is not associated with any set-aside program. Amerisourcebergen, a major supplier of...
  • SPE2DB22D2206
    Indefinite Delivery Contract
  • SPE2DB22D2206-SPE2DB24FHW37
    Delivery Order

This is a federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, for the supply of ULTOMIRIS 1,100 MG/11 ML VIAL 11ML. The contract, valued at $51,082.04, is a delivery order placed by the Defense Logistics Agency (DLA), a defense agency, and has a completion date of July 15, 2024. The contract is a Firm Fixed Price arrangement with no set-aside designation.

AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at $750,000 through May 2024, covering similar medical products and prescription drugs.

Generated 5/17/25, 10:09 AM